– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing disability progression in PPMS – – Fenebrutinib …

Emerging research has provided fresh evidence regarding the role of viral infection in the development of multiple sclerosis. By analyzing immune cells extracted from the spinal fluid of patients, scientists identified a specific population of “killer” T …

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis …

Could plastic byproducts and forever chemicals found in drinking water cause your body to attack your own nervous system?  New research from Sweden links higher levels of per- and polyfluoroalkyl substances, or  PFAS, and polychlorinated biphenyls, or PCBs …

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in …

Multiple sclerosis (MS) is a disease in which the immune system erroneously attacks a protective insulation that surrounds neurons, known as myelin. As myelin degenerates, it leads to a variety of other problems with sensation and movement. MS can very …

Four of the Republican candidates running for governor say they support a ban on vaccines developed with mRNA technology, like the Moderna and Pfizer COVID vaccines. The subject came up during this week’s debate sponsored by Moms for Liberty. Zach Lahn, a …

One of the leading triggers for multiple sclerosis (MS) is an infection with the Epstein-Barr virus. However, certain gene variants also play an important role. Researchers at the University of Zurich have now shown that it is the molecular interaction …

Doctors have long been hamstrung in their efforts to help patients with multiple sclerosis, and limited to treatments that only target the disease’s highly variable symptoms.  Despite the approval of the first disease-modifying therapy Betaseron in 1993 …

The past year brought forth critical developments in multiple sclerosis (MS) research, focusing heavily on optimizing current treatments and advancing novel mechanisms to address the progressive forms of the disease. From definitive data confirming the …